Supreme Pharmacist System

At 10 am on June 6, 2022, Huanyu Bio held a grand press conference at the Jiangzhou International Conference Center.

In the past year or so, Huanyu Bio has held a press conference every three to five times, and every time it is a major breakthrough in medicine or technological innovation.

Because of this, as soon as the news was released, countless reporters from home and abroad flocked to it, and thousands of reporters filled the huge press hall to the brim.

Lin Wei, vice president and chief press officer of Huanyu Bio, presided over the press conference.

Under the gaze of countless reporters, Lin Wei said excitedly: "Good morning, all guests, journalists and friends, welcome to participate in Huanyu's press conference..."

Ka Ka Ka! ! !

During the interval between Lin Wei's speeches, the release hall instantly became a sea of ​​spotlights.

Lin Wei paused and said: "Here I want to tell you a piece of good news. Under the leadership of Huanyu Biological Chief Scientist Zhou Wen, Senior Engineer Lin Ming, and Academician He Junfeng, Deputy Director and Chief Scientist of the Institute of Hepatitis B, Chinese Academy of Sciences , and with the continuous efforts of hundreds of other researchers, we have successfully conquered hepatitis B virus!"

The conference site was a little quiet at first, but in the next second, there was a huge buzzing sound.

"What do you mean, has a new drug been developed?"

"I still don't understand, conquering is healing!"

"Impossible, hepatitis B virus can't be cured."

"I do not know……"

Lin Wei gave the on-site reporters more than ten seconds to digest what he just said, and then explained their research results.

When the reporters at the scene learned that this drug will cure nearly 300 million hepatitis B virus patients around the world, heated discussions erupted immediately.

...

The news that the hepatitis B virus was conquered spread all over the world in an instant.

When countless hepatitis B patients saw this news, they were naturally extremely excited.

However, some dozen pharmaceutical companies that are researching new drugs for hepatitis B and have even reached the clinical trial stage were struck by lightning when they heard the news.

Especially those 6 pharmaceutical companies that got the data of Huanyu Biological Formula, they spent so much energy on this matter, they did not expect that all of them did nothing in the end.

...

In the inner ring of Kyoto, in a building that hangs the national emblem.

A man with a square face was reading an internal reference news, and soon read the news.

A slightly surprised look appeared on his face, and he asked in a deep voice, "Is this news true?"

The confidential secretary next to him who was sorting out the information immediately said respectfully: "Yes, sir, the experts from the Food and Drug Administration have tested it with DGD technology, and it is absolutely true."

The man with the square face nodded, a smile appeared on his serious face, and he said with a smile: "No wonder you dare to promise me, it seems that you have already prepared!"

The confidential secretary smiled and said: "Yes! Professor Zhou's level in the medical field is indeed worthy of the word "miracle doctor."

It is self-evident how important DGD technology is to pharmaceutical companies, and it can be regarded as one of the greatest inventions in the pharmaceutical industry.

This kind of high-tech technology is not something Huanyu Biology can disclose if it wants to, and must obtain the consent of the national level.

The same is true for European and American countries. The technology of European and American companies cannot be exported to China casually.

So it is conceivable that when Huanyu Biology proposed DGD technology sharing, how fierce was the opposition?

Including many upper-level bosses who trusted Zhou Wen, they also opposed it.

However, Zhou Wen still convinced a bunch of big shots.

Zhou Wen's reason is very good. DGD technology is important, but if you want to regain the standard of the global pharmaceutical market, relying on a DGD technology is far from enough.

First of all, NMPA has always followed the lead of the FDA, and freezing three feet is not a one-day cold, and it is not a day or two to completely reverse this situation.

Because there are many interests involved.

Where there are interests, there will be disputes. Many people are unwilling to leave the comfort zone and explore unknown areas. If they do well, the credit goes to the leaders. The domestic promotion encountered great resistance.

The second and most important point is that European and American countries will certainly not allow DGD technology whose core technology is mastered by Chinese companies to be implemented in their own countries. Even if the academic circle supports it, it is useless for pharmaceutical companies to advocate it.

Don't even think about it.

Then the problem arises, even if China’s NMPA adopts the DGD technical standard, if the drug developed by Huanyu Biotech wants to be sold abroad, it still needs to go through the time-consuming and lengthy clinical trial procedure again.

Some people may say that it is their business that European and American countries are willing to stand still. At worst, they can just sell them in China.

But Zhou Wen couldn't wait any longer. His new drug research and development speed far exceeded the imagination of ordinary people. He had a lot of new drugs in his hand that needed to be introduced to the market. Fast-to-market like wrinkle cream.

And DGD technology is the stepping stone to open up the European and American pharmaceutical market.

With the speed of Zhou Wen's drug research and development, European and American pharmaceutical companies combined are not enough for him to fight.

Therefore, sharing DGD technology with Europe and the United States is not for the convenience of European and American countries, but for their own convenience.

Of course, these ordinary people cannot know.

The reason why the upper-level leaders agreed to Zhou Wen was only because of his medical skills.

Zhou Wen's medical skills have almost reached the point of perfection, and the master of traditional Chinese medicine is no longer enough to describe him. The bosses and family members above all call him "miracle doctor" now.

One can imagine the weight of his words?

Therefore, when he patted his chest and assured the chiefs that he would earn back the DGD technology with profits, the chiefs finally agreed to his proposal.

Now it seems that Zhou Wen has already prepared his trump card!

...

...

Half a month later.

The "Qingganling Preparation" code-named PD0079 developed by Huanyu Biologics, as well as the second-class new drugs of four or five other pharmaceutical companies, became the first batch of experimental subjects of DGD technology in China and conducted the first phase of clinical trials.

It usually takes 3 to 6 months for the first phase of clinical trials. After using DGD technology, it took only one week to complete the trials.

Of course, "Qingganling Preparation" passed the first phase of clinical trials without any accidents.

As soon as the news came out, it immediately caused a huge sensation.

Numerous pharmaceutical laboratories and pharmaceutical companies are surprised and extremely envious of the high efficiency and rapidity of DGD technology.

Relevant departments in Europe, America, Japan, and South Korea have also accelerated the approval of DGD technology.

Soon, Han Country became the second country to adopt DGD technology.

Japan followed closely behind.

Then Germany, Portugal, France, Italy, Russia...

And at such a speed like a competition, "Qingganling Preparation" has passed the second phase of clinical trials.

Everything is ready to go...

The genius remembers the address of this site in one second:. Mobile version reading URL: